• Je něco špatně v tomto záznamu ?

Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

P. Geusens, F. Marin, DL. Kendler, LA. Russo, CA. Zerbini, S. Minisola, JJ. Body, E. Lespessailles, SL. Greenspan, A. Bagur, JJ. Stepan, P. Lakatos, E. Casado, R. Moericke, P. López-Romero, A. Fahrleitner-Pammer,

. 2018 ; 33 (5) : 783-794. [pub] 20180209

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19045568

The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and bone mineral density (BMD) T-score ≤-1.5. Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and nonvertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate. Here we present the prospectively planned subgroup analyses of fracture data across subgroups, which were predefined by the following baseline characteristics: age, number and severity of prevalent VFx, prevalent nonvertebral fractures (NVFx), glucocorticoid use, prior osteoporosis drugs, recent bisphosphonate use, clinical VFx in the year before study entry, and baseline BMD. Heterogeneity of the treatment effect on the primary endpoint (new VFx), and the four key secondary endpoints (including clinical fractures and NVFFx) were investigated by logistic and Cox proportional hazards regression models. A total of 1360 women were randomized and treated (680 per group). Mean age was 72.1 years, mean (SD) number of prevalent VFx was 2.7 (2.1), 55.4% had a BMD T-score <-2.5, 36.5% had a recent clinical VFx, 28.3% had a prior major NVFx, 43.2% were osteoporosis drug-naïve, 39.3% were recent bisphosphonate users, and 9.3% were taking glucocorticoids at a prednisone-equivalent dose of >5 mg/d. For most fracture endpoints, the risk reduction of teriparatide versus risedronate did not significantly differ in any of the subgroups analyzed (treatment-by-subgroup interaction p > 0.1), with most subgroups mirroring results from the total study population. In conclusion, in postmenopausal women with severe osteoporosis, the antifracture efficacy of teriparatide compared with risedronate was consistent in a wide range of patient settings, including treatment-naïve and previously treated patients. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045568
003      
CZ-PrNML
005      
20200115082049.0
007      
ta
008      
200109s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jbmr.3384 $2 doi
035    __
$a (PubMed)29329484
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Geusens, Piet $u Maastricht University Medical Center, Maastricht, The Netherlands.
245    10
$a Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial / $c P. Geusens, F. Marin, DL. Kendler, LA. Russo, CA. Zerbini, S. Minisola, JJ. Body, E. Lespessailles, SL. Greenspan, A. Bagur, JJ. Stepan, P. Lakatos, E. Casado, R. Moericke, P. López-Romero, A. Fahrleitner-Pammer,
520    9_
$a The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), and bone mineral density (BMD) T-score ≤-1.5. Patients were treated with either s.c. daily teriparatide 20 μg or oral weekly risedronate 35 mg. As previously reported, the risk of new VFx and clinical fractures (a composite of clinical VFx and nonvertebral fragility fractures [NVFFx]) was statistically significantly reduced with teriparatide compared with risedronate. Here we present the prospectively planned subgroup analyses of fracture data across subgroups, which were predefined by the following baseline characteristics: age, number and severity of prevalent VFx, prevalent nonvertebral fractures (NVFx), glucocorticoid use, prior osteoporosis drugs, recent bisphosphonate use, clinical VFx in the year before study entry, and baseline BMD. Heterogeneity of the treatment effect on the primary endpoint (new VFx), and the four key secondary endpoints (including clinical fractures and NVFFx) were investigated by logistic and Cox proportional hazards regression models. A total of 1360 women were randomized and treated (680 per group). Mean age was 72.1 years, mean (SD) number of prevalent VFx was 2.7 (2.1), 55.4% had a BMD T-score <-2.5, 36.5% had a recent clinical VFx, 28.3% had a prior major NVFx, 43.2% were osteoporosis drug-naïve, 39.3% were recent bisphosphonate users, and 9.3% were taking glucocorticoids at a prednisone-equivalent dose of >5 mg/d. For most fracture endpoints, the risk reduction of teriparatide versus risedronate did not significantly differ in any of the subgroups analyzed (treatment-by-subgroup interaction p > 0.1), with most subgroups mirroring results from the total study population. In conclusion, in postmenopausal women with severe osteoporosis, the antifracture efficacy of teriparatide compared with risedronate was consistent in a wide range of patient settings, including treatment-naïve and previously treated patients. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.
650    _2
$a senioři $7 D000368
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a osteoporóza $x farmakoterapie $x metabolismus $x patologie $7 D010024
650    12
$a postmenopauza $7 D017698
650    _2
$a kyselina risedronová $x aplikace a dávkování $7 D000068296
650    _2
$a rizikové faktory $7 D012307
650    _2
$a fraktury páteře $x farmakoterapie $x metabolismus $x patologie $7 D016103
650    _2
$a teriparatid $x aplikace a dávkování $7 D019379
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Marin, Fernando $u Lilly Research Center Europe, Madrid, Spain.
700    1_
$a Kendler, David L $u University of British Columbia, Vancouver, Canada.
700    1_
$a Russo, Luis A $u CCBR Brasil Centro de Analises e Pesquisas Clínicas, Rio de Janeiro, Brazil.
700    1_
$a Zerbini, Cristiano Af $u Centro Paulista de Investigaçao Clínica, Sao Paulo, Brazil.
700    1_
$a Minisola, Salvatore $u "Sapienza" Rome University, Rome, Italy.
700    1_
$a Body, Jean Jacques $u CHU Brugmann, ULB, Brussels, Belgium.
700    1_
$a Lespessailles, Eric $u Regional Hospital of Orléans, Orléans, France.
700    1_
$a Greenspan, Susan L $u Osteoporosis Center, University of Pittsburgh, Pittsburgh, PA, USA.
700    1_
$a Bagur, Alicia $u Centro de Osteopatías Comlit, Buenos Aires, Argentina.
700    1_
$a Stepan, Jan J $u Institute of Rheumatology and Faculty of Medicine 1, Charles University, Prague, Czech Republic.
700    1_
$a Lakatos, Péter $u Semmelweis University Medical School, Budapest, Hungary.
700    1_
$a Casado, Enrique $u University Hospital Parc Taulí Sabadell (UAB), Barcelona, Spain.
700    1_
$a Moericke, Rüdiger $u Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany.
700    1_
$a López-Romero, Pedro $u Lilly Research Center Europe, Madrid, Spain.
700    1_
$a Fahrleitner-Pammer, Astrid $u Division of Endocrinology and Diabetes, Medical University of Graz, Graz, Austria.
773    0_
$w MED00002559 $t Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research $x 1523-4681 $g Roč. 33, č. 5 (2018), s. 783-794
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29329484 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200115082423 $b ABA008
999    __
$a ok $b bmc $g 1483836 $s 1084241
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 33 $c 5 $d 783-794 $e 20180209 $i 1523-4681 $m Journal of bone and mineral research $n J Bone Miner Res $x MED00002559
LZP    __
$a Pubmed-20200109

Najít záznam

Citační ukazatele

Možnosti archivace